Topic: central nervous system
Johnson & Johnson unit Janssen joins the Alzheimer's failure club after deciding to stop trials of its BACE inhibitor atabacestat.
EIP Pharma is enrolling a phase 2b trial of neflamapimod, which targets synaptic dysfunction.
Alnylam is gearing up to move RNAi therapies for central nervous system disorders into the clinic.
Johnson & Johnson looks increasingly like it is onto a winner with esketamine for resistant depression—though one phase 3 trial missed the mark.
Alder says data showing its IV drug eptinezumab can extend pain-free days between migraines makes it an important treatment option.
Roche snapped up a remyelinating drug candidate for multiple sclerosis from an alliance with Versant that also spawned startup Pipeline Therapeutics.
Switching on the LZK gene in mice with spinal cord injuries led to a smaller scar, which might improve healing.
Reckitt Benkiser spinout Indivior agreed to a $294 million deal with C4X Discovery for a drug candidate to treat addiction.
The revisions see Abide regain control of a phase 2-ready CNS drug and pocket an upfront fee in exchange for an earlier-stage drug.
Biohaven says it has two positive phase 3 trials in hand for its oral CGRP inhibitor for migraine, setting up a filing next year, although investors seemed to be spooked by the data.